Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
TGI-2 by Hefei TG ImmunoPharma for Metastatic Ovarian Cancer: Likelihood of Approval
TGI-2 is under clinical development by Hefei TG ImmunoPharma and currently in Phase I for Metastatic Ovarian Cancer. According to...
TGI-2 by Hefei TG ImmunoPharma for Metastatic Colorectal Cancer: Likelihood of Approval
TGI-2 is under clinical development by Hefei TG ImmunoPharma and currently in Phase I for Metastatic Colorectal Cancer. According to...
TGI-2 by Hefei TG ImmunoPharma for Solid Tumor: Likelihood of Approval
TGI-2 is under clinical development by Hefei TG ImmunoPharma and currently in Phase I for Solid Tumor. According to GlobalData,...
TGI-2 by Hefei TG ImmunoPharma for Metastatic Melanoma: Likelihood of Approval
TGI-2 is under clinical development by Hefei TG ImmunoPharma and currently in Phase I for Metastatic Melanoma. According to GlobalData,...